• br In vivo actions of GLP

  2022-05-09

  

  In vivo actions of GLP-1/GLP-1R agonists on the vascular endothelium Using contrast-enhanced ultrasound, male Sprague Dawley rats receiving an intravenous infusion of native GLP-1 (30 pmol/kg/min) for 2 h demonstrated significant improvements in both microvascular blood volume and microvascular b

• Chlorogenic acid br Introduction The glucagon receptor GCGR

  2022-05-09

  

  Introduction The glucagon receptor (GCGR) is a G-protein-coupled receptor expressed mainly in the liver and kidney. Upon glucagon binding, it activates the stimulatory G protein (Gs) and increases cAMP level, subsequently transducing glucagon signaling involved in glucose, amino acids and lipid m

• The patterns of Fig Fig emerge at the multicellular level

  2022-05-09

  

  The patterns of Fig. 1, Fig. 2 emerge at the multicellular level; their dynamics can only be understood by integrating different magnitudes and feedback loops in networks incorporating the coupling between biochemical and bioelectrical signals (see Fig. 6, Fig. 8). Interestingly, this might also be

• Galanin mediates its activity by binding

  2022-05-09

  

  Galanin mediates its activity by binding to three G-protein coupled receptor subtypes (designated GAL1-GAL3). Since GAL3 mRNA is found mainly in regions of the mesolimbic dopamine system, such as the ventral tegmental area, dorsal raphe nucleus, LC, amygdala, hippocampus, thalamus, hypothalamus, NAc

• br Materials and methods br Results br Discussion Although

  2022-05-09

  

  Materials and methods Results Discussion Although homologues of the β-galactosidase gene were known to exist in the Xenopus genome, and SA-β-gal activity has been detected in whole-mount Xenopus embryos by histochemical staining (Davaapil et al., 2017), no reports have been presented so far

• br Experimental br Results and discussions br Conclusion br

  2022-05-09

  

  Experimental Results and discussions Conclusion Notes Introduction The noncanonical DNA structures that is, i-motif [[1], [2], [3], [4], [5], [6], [7], [8], [9]] and G-quadruplex [[10], [11], [12], [13], [14]] have recently been carefully studied using either experimental or computati

• VS strategies have been building momentum in G drug

  2022-05-09

  

  VS strategies have been building momentum in G4 drug discovery both as a low-cost enrichment step and as a lead development step in the discovery pipeline, which our laboratory has previously discussed [31]. Whereas traditional HTS methods rely on obtaining and screening hundreds or thousands of com

• br Chemistry Analog has been previously reported by our

  2022-05-09

  

  Chemistry Analog 12 has been previously reported by our group. Experimental procedures for the synthesis and characterization of 13–32 are available in Scheme 1, Schemes S1–S9 and Table S1 in Supplementary data. Preparation of 30 and 31 is depicted in Scheme 1 as the representative example. Commo

• All of the abovementioned effects of PUFAs

  2022-05-09

  

  All of the abovementioned effects of PUFAs signal their involvement in a cellular phenotype switching phenomenon, which is increasingly recognized as a potential target for future pharmacotherapies of atherosclerosis, especially for individuals who do not respond to the classical lipid-lowering stra

• A previous study from our institution showed

  2022-05-09

  

  A previous study from our institution showed moderate correlation between the APTT and Anti-FXa assays, prompting an institution-wide change to an Anti-FXa based monitoring of unfractionated heparin. The current study is a descriptive analysis to evaluate the clinical outcomes in this pediatric coho

• br Introduction br The histaminergic system in

  2022-05-09

  

  Introduction The histaminergic system in the central nervous system The Tariquidar methanesulfonate, hydrate is continually processing information through aminergic systems present in the mammalian CNS such as the serotonergic, dopaminergic, noradrenergic and histaminergic systems which functi

• br ABT aR aR methyl hexahydropyrrolo b

  2022-05-09

  

  ABT-288 (2-[4'-((3aR,6aR)-5-methyl-hexahydropyrrolo[3,4-b]pyrrol-1-yl)-biphenyl-4-yl]2H-pyridazine-3-one) is a selective H3R antagonist/inverse agonist developed by Abbott. Structurally, it is a compound with molecular weight (MW) 372.46 g/mol, three H-bond acceptors (HBA), and Moriguchi LogP (MLo

• The concentration of rapamycin that gave half

  2022-05-09

  

  The concentration of rapamycin that gave half-maximal induction of the expression of HO-1 and Prx-1 mRNA in normal hepatocytes was 0.05 μM, with maximal induction at about 0.1 μM rapamycin. While, at rapamycin concentrations higher than 0.1 μM, the degree of enzyme induction decreased, elevated expr

• Our synthetic approach to GPR

  2022-05-07

  

  Our synthetic approach to GPR55 antagonists was designed so that many different structures could be accessed to rapidly explore initial SAR, along with validating or modifying our current model (). The synthesis begins with the coupling of a carboxylic Zinc protoporphyrin IX to 4-piperidone by first

• PF 1022A br Conflict of Interest Both GM

  2022-05-07

  

  Conflict of Interest Both GM and BDH are shareholders in Caldan Therapeutics, a company exploring potential novel treatments for type 2 diabetes. Acknowledgments Work described herein was supported by Biotechnology and Biological Sciences Research Council [grant BB/K019864/1)] (to GM) and [gr

16022 records 427/1069 page Previous Next First page 上5页 426427428429430 下5页 Last page